Received Feb 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (TRUMENBA) | PFIZER\WYETH | 1 | GP8622 | IM / RA |
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | NR394 | IM / RA |
Minor attends vaccination clinic on 01/08/2024 for the administration of his 16-year-old vaccines, menveo (MCV) and trumemba (MCV B) are administered with a booster dose in 6 months. Minor arrives today 04/02/2025 for administration of the 2nd dose of trumemenba (MCV B) when validating the vaccine in the system indicates an invalidation in the area of the trumemba vaccine (MCV B) administered on 01/08/2024 since the minor received the bexsero vaccine (MCV B) in 2019. It is validated with the health department, vaccination division area and notification was received via email from doctor with the indication that Bexsero (MCV B) be administered since she was started with it. Her primary doctor and mother are notified of the event, she expresses her understanding, and the minor is vaccinated. At the time of the interview with the mother, the same verbal statement was made: "The minor has not presented any changes or symptoms."
No
No
No
No
Not applicable